Heptapharmacological activity of Quercetin-3-O-phosphate against lung cancer pathways

Maryam Abdulrahman Alahdal1, Hadil Alahdal2, Najat Binothman3,4

  • 1College of Science, Department of Biology, Umm Al-Qura University, Makkah, Saudi Arabia.

Plos One
|July 10, 2026
PubMed

Insights

This study explored Quercetin-3-O-Phosphate as a multitargeted drug for lung cancer, identifying it as a promising candidate to overcome drug resistance. Further evaluation is recommended for clinical confirmation.

Area of Science:

  • Oncology
  • Computational Chemistry
  • Drug Discovery

Background:

  • Lung cancer causes significant global mortality, with drug resistance posing a major treatment challenge.
  • Multitargeted drug design offers a strategy to overcome resistance and enhance therapeutic efficacy.
  • Identifying novel compounds that can inhibit multiple cancer pathways is crucial.

Purpose of the Study:

  • To identify potential multitargeted drug candidates for lung cancer treatment.
  • To investigate the efficacy of Quercetin-3-O-Phosphate against identified lung cancer targets.
  • To assess the binding affinity and stability of Quercetin-3-O-Phosphate through computational methods.

Main Methods:

  • Identified lung cancer-associated proteins (CK2, Ran-Importin β complex, HNGF, Human Survivin, CRK-II, AKR1B10, tRNA synthase 2) with PDB IDs.
  • Performed molecular docking (HTVS, SP, XP) using DrugBank's library and MM/GBSA.
  • Conducted DFT, pharmacokinetics, WaterMap, and MD simulations (100 ns) to evaluate compound stability and interactions.

Main Results:

  • Quercetin-3-O-Phosphate emerged as the top compound from multitarget docking analysis.
  • The compound exhibited favorable docking and MM/GBSA scores, indicating strong binding affinity.
  • Molecular dynamics and WaterMap simulations confirmed stable interactions and key hydration sites, supporting its potential efficacy.

Conclusions:

  • Quercetin-3-O-Phosphate demonstrates significant potential as a multitargeted therapeutic agent for lung cancer.
  • Computational analyses support its further evaluation, meeting all required criteria for drug development.
  • Experimental validation is necessary to confirm its clinical efficacy in lung cancer treatment.

Related Concept Videos